CAT3 (Figure 1A) is a novel phenanthroindolizidine substance that selectively inhibits the hedgehog signaling pathway, demonstrating a significant inhibitory effect in GBM and TMZ-resistant GBM in orthotopic glioblastoma mice models following oral administration [8,9,10]. The gene discussed is SLC7A3; the disease is glioblastoma.